Pneumoccocal Immunisation Clinical Trial
Official title:
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years
Primary Objective: - To assess the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination - To assess the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
The duration of each participant's participation will be approximately 6 months. ;